Dipeptidyl peptidase 4 promotes epithelial cell transformation and breast tumourigenesis via induction of PIN1 gene expression

British Journal of Pharmacology

Volumn 172, Issue 21, 2015, Pages 5096-5109

  Choi, H J ^a   Kim, J Y ^a   Lim, S C ^b   Kim, G ^a   Yun, H J ^a   Choi, H S ^a  

^a Chosun University   (South Korea)

^b Chosun University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; DIPEPTIDYL PEPTIDASE IV; JUGLONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PEPTIDYLPROLYL ISOMERASE PIN1; PROTEIN C JUN; SITAGLIPTIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR E2F1; EPIDERMAL GROWTH FACTOR; NIMA INTERACTING PEPTIDYLPROLYL ISOMERASE; PEPTIDYLPROLYL ISOMERASE; PIN1 PROTEIN, HUMAN; PIN1 PROTEIN, MOUSE; PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INHIBITION; CARCINOGENICITY; CELL TRANSFORMATION; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; EPITHELIUM CELL; FEMALE; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MCF 7 CELL LINE; MOUSE; NONHUMAN; PIN1 GENE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; BIOSYNTHESIS; BREAST TUMOR; DRUG EFFECTS; ENZYMOLOGY; GENETICS; MCF-7 CELL LINE; METABOLISM; PATHOLOGY;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; DIPEPTIDYL PEPTIDASE 4; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; MCF-7 CELLS; MICE; MICE, INBRED BALB C; NIMA-INTERACTING PEPTIDYLPROLYL ISOMERASE; PEPTIDYLPROLYL ISOMERASE; PROTEIN KINASES; SIGNAL TRANSDUCTION; SITAGLIPTIN PHOSPHATE; TRANSCRIPTION FACTOR AP-1; UP-REGULATION;

EID: 84945950222     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13274     Document Type: Article

References (56)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al., (2013). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
2. Alt JR, Cleveland JL, Hannink M, Diehl JA, (2000). Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 14: 3102-3114.
3. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE, et al., (2006). Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29: 2632-2637.
4. Boonacker E, Van Noorden CJ, (2003). The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 82: 53-73.
5. Carbone A, Gloghini A, Zagonel V, Aldinucci D, Gattei V, Degan M, et al., (1995). The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin's lymphomas/leukemias. Blood 86: 4617-4626.
6. Cordero OJ, Ayude D, Nogueira M, Rodriguez-Berrocal FJ, de la Cadena MP, (2000). Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer. Br J Cancer 83: 1139-1146.
7. de Andrade CF, Bigni R, Pombo-de-Oliveira MS, Alves G, Pereira DA, (2009). CD26/DPPIV cell membrane expression and DPPIV activity in plasma of patients with acute leukemia. J Enzyme Inhib Med Chem 24: 708-714.
8. Deacon CF, Holst JJ, (2009). Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Adv Ther 26: 488-499.
9. Dimitrova M, Ivanov I, Todorova R, Stefanova N, Moskova-Doumanova V, Topouzova-Hristova T, et al., (2012). Comparison of the activity levels and localization of dipeptidyl peptidase IV in normal and tumor human lung cells. Tissue Cell 44: 74-79.
10. Drucker DJ, Nauck MA, (2006). The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705.
11. Eferl R, Wagner EF, (2003). AP-1: a double-edged sword in tumorigenesis. Nature reviews. Cancer 3: 859-868.
12. Farag SS, Srivastava S, Messina-Graham S, Schwartz J, Robertson MJ, Abonour R, et al., (2013). In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies. Stem Cells Dev 22: 1007-1015.
13. Fleischer B, (1994). CD26: a surface protease involved in T-cell activation. Immunol Today 15: 180-184.
14. Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A, et al., (2008). The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 114: 23-37.
15. Fukuchi M, Fukai Y, Kimura H, Sohda M, Miyazaki T, Nakajima M, et al., (2006). Prolyl isomerase Pin1 expression predicts prognosis in patients with esophageal squamous cell carcinoma and correlates with cyclinD1 expression. Int J Oncol 29: 329-334.
16. Hanski C, Huhle T, Reutter W, (1985). Involvement of plasma membrane dipeptidyl peptidase IV in fibronectin-mediated adhesion of cells on collagen. Biol Chem Hoppe Seyler 366: 1169-1176.
17. Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH, (2009). CD26 expression on T cell lines increases SDF-1-alpha-mediated invasion. Br J Cancer 101: 983-991.
18. Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH, (2008). The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci 13: 1634-1645.
19. Heike M, Mobius U, Knuth A, Meuer S, Meyer zum Buschenfelde KH, (1988). Tissue distribution of the T cell activation antigen Ta1. Serological, immunohistochemical and biochemical investigations. Clin Exp Immunol 74: 431-434.
20. Hunter T, (1998). Prolyl isomerases and nuclear function. Cell 92: 141-143.
21. Iwata S, Morimoto C, (1999). CD26/dipeptidyl peptidase IV in context. The different roles of a multifunctional ectoenzyme in malignant transformation. J Exp Med 190: 301-306.
22. Kajiyama H, Kikkawa F, Khin E, Shibata K, Ino K, Mizutani S, (2003). Dipeptidyl peptidase IV overexpression induces up-regulation of E-cadherin and tissue inhibitors of matrix metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells. Cancer Res 63: 2278-2283.
23. Kajiyama H, Kikkawa F, Suzuki T, Shibata K, Ino K, Mizutani S, (2002). Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma. Cancer Res 62: 2753-2757.
24. Karin M, (1995). The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 270: 16483-16486.
25. Khanal P, Namgoong GM, Kang BS, Woo ER, Choi HS, (2010). The prolyl isomerase Pin1 enhances HER-2 expression and cellular transformation via its interaction with mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1. Mol Cancer Ther 9: 606-616.
26. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, Group NCRRGW (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160 (7): 1577-1579.
27. Kim K, Kim G, Kim JY, Yun HJ, Lim SC, Choi HS, (2014). Interleukin-22 promotes epithelial cell transformation and breast tumorigenesis via MAP3K8 activation. Carcinogenesis 35: 1352-1361.
28. Larsson SC, Mantzoros CS, Wolk A, (2007). Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 121: 856-862.
29. Liou YC, Zhou XZ, Lu KP, (2011). Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins. Trends Biochem Sci 36: 501-514.
30. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE, (2008). The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat 109: 389-395.
31. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE, (2006). Increased prevalence of prior breast cancer in women with newly diagnosed diabetes. Breast Cancer Res Treat 98: 303-309.
32. Loster K, Zeilinger K, Schuppan D, Reutter W, (1995). The cysteine-rich region of dipeptidyl peptidase IV (CD 26) is the collagen-binding site. Biochem Biophys Res Commun 217: 341-348.
33. Lu KP, Zhou XZ, (2007). The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol 8: 904-916.
34. Lufei C, Koh TH, Uchida T, Cao X, (2007). Pin1 is required for the Ser727 phosphorylation-dependent Stat3 activity. Oncogene 26: 7656-7664.
35. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
36. Mentlein R, (1999). Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85: 9-24.
37. Mizutani S, Sumi S, Narita O, Tomoda Y, (1985). Purification and properties of human placental dipeptidyl peptidase IV. Nihon Sanka Fujinka Gakkai zasshi 37: 769-775.
38. Namgoong GM, Khanal P, Cho HG, Lim SC, Oh YK, Kang BS, et al., (2010). The prolyl isomerase Pin1 induces LC-3 expression and mediates tamoxifen resistance in breast cancer. J Biol Chem 285: 23829-23841.
39. Nemoto E, Sugawara S, Takada H, Shoji S, Horiuch H, (1999). Increase of CD26/dipeptidyl peptidase IV expression on human gingival fibroblasts upon stimulation with cytokines and bacterial components. Infect Immun 67: 6225-6233.
40. Onitilo AA, Stankowski RV, Berg RL, Engel JM, Glurich I, Williams GM, et al., (2014). Breast cancer incidence before and after diagnosis of type 2 diabetes mellitus in women: increased risk in the prediabetes phase. Eur J Cancer Prev 23: 76-83.
41. Oravecz T, Pall M, Roderiquez G, Gorrell MD, Ditto M, Nguyen NY, et al., (1997). Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med 186: 1865-1872.
42. Park JE, Lee JA, Park SG, Lee DH, Kim SJ, Kim HJ, et al., (2012). A critical step for JNK activation: isomerization by the prolyl isomerase Pin1. Cell Death Differ 19: 153-161.
43. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al., (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-1106.
44. Ribatti D, Nico B, Ranieri G, Specchia G, Vacca A, (2013). The role of angiogenesis in human non-Hodgkin lymphomas. Neoplasia 15: 231-238.
45. Roesch A, Wittschier S, Becker B, Landthaler M, Vogt T, (2006). Loss of dipeptidyl peptidase IV immunostaining discriminates malignant melanomas from deep penetrating nevi. Mod Pathol 19: 1378-1385.
46. Ryo A, Liou YC, Wulf G, Nakamura M, Lee SW, Lu KP, (2002). PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells. Mol Cell Biol 22: 5281-5295.
47. Ryo A, Nakamura M, Wulf G, Liou YC, Lu KP, (2001). Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol 3: 793-801.
48. Ryo A, Suizu F, Yoshida Y, Perrem K, Liou YC, Wulf G, et al., (2003). Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell 12: 1413-1426.
49. Stecca BA, Nardo B, Chieco P, Mazziotti A, Bolondi L, Cavallari A, (1997). Aberrant dipeptidyl peptidase IV (DPP IV/CD26) expression in human hepatocellular carcinoma. J Hepatol 27: 337-345.
50. Varona A, Blanco L, Perez I, Gil J, Irazusta J, Lopez JI, et al., (2010). Expression and activity profiles of DPP IV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent. BMC Cancer 10: 193.
51. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al., (2001). Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86: 1930-1935.
52. Wulf GM, Ryo A, Wulf GG, Lee SW, Niu T, Petkova V, et al., (2001). Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J 20: 3459-3472.
53. Yao TW, Kim WS, Yu DM, Sharbeen G, McCaughan GW, Choi KY, et al., (2011). A novel role of dipeptidyl peptidase 9 in epidermal growth factor signaling. Mol Cancer Res 9: 948-959.
54. Zhang SY, Liu SC, Al-Saleem LF, Holloran D, Babb J, Guo X, et al., (2000). E2F-1: a proliferative marker of breast neoplasia. Cancer Epidemiol Biomarkers Prev 9: 395-401.
55. Zheng H, You H, Zhou XZ, Murray SA, Uchida T, Wulf G, et al., (2002). The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature 419: 849-853.
56. Zhou XZ, Lu PJ, Wulf G, Lu KP, (1999). Phosphorylation-dependent prolyl isomerization: a novel signaling regulatory mechanism. Cell Mol Life Sci 56: 788806.